Lymphoma Clinical Trials

Official title: Optimizing lymphoDepletion to Improve Outcomes In Patients Receiving Cell Therapy With Yescarta

DLBCL - Diffuse Large B Cell Lymphoma · University Health Network, Toronto

Comparing Zilovertamab vedotin with Vincristine for diffuse large b-cell lymphoma

Explore this study →

Sites in Edmonton, Halifax and 3 more cities

Official title: A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

Diffuse Large B-Cell Lymphoma · Merck Sharp & Dohme LLC

Comparing KITE-753 with Axicabtagene Ciloleucel for relapsed or refractory large b-cell lymphoma

Explore this study →

Sites in Montreal and Québec

Official title: Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy

Relapsed or Refractory Large B-cell Lymphoma · Kite, A Gilead Company

Get them matched to the best-fit trials

Answer a few questions and we'll find the closest matches for lymphoma.

Comparing CPA with DPX-Survivac for relapsed diffuse large b-cell lymphoma

Explore this study →

One site, in Saskatoon

Official title: DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Relapsed Diffuse Large B-cell Lymphoma · ImmunoVaccine Technologies, Inc. (IMV Inc.)

Comparing Bleomycin with Brentuximab vedotin for Hodgkin lymphoma

Explore this study →

Sites in Halifax, Hamilton and 5 more cities

Official title: Brentuximab Vedotin in Early Stage Hodgkin Lymphoma

Hodgkin Lymphoma · University College, London

Comparing Odronextamab with Rituximab for follicular lymphoma (FL)

Explore this study →

Sites in Calgary, Greenfield Park and 3 more cities

Official title: A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

Follicular Lymphoma (FL) · Regeneron Pharmaceuticals

Comparing 5 approaches for b-cell non-hodgkin lymphoma

Explore this study →

One site, in Montreal

Official title: IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas

B-cell Non-Hodgkin Lymphoma · Iksuda Therapeutics Ltd.

Testing zamtocabtagene autoleucel with Cyclophosphamide for refractory diffuse large b cell lymphoma (DLBCL)

Explore this study →

Sites in Edmonton and Toronto

Official title: DALY II USA/ MB-CART2019.1 for DLBCL

Refractory Diffuse Large B Cell Lymphoma (DLBCL) · Miltenyi Biomedicine GmbH

Testing Surovatamig for b-cell non-hodgkin lymphoma

Explore this study →

Sites in Barrie, Brampton and 2 more cities

Official title: Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL

B-cell Non-Hodgkin Lymphoma · AstraZeneca

Comparing Golcadomide with Lenalidomide for follicular lymphoma

Explore this study →

Sites in Sherbrooke, Québec and 2 more cities

Official title: A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

Follicular Lymphoma · Celgene

Comparing 5 approaches for peripheral t cell lymphoma

Explore this study →

Sites in Ottawa and Toronto

Official title: To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL

Peripheral T Cell Lymphoma · Acrotech Biopharma Inc.

Comparing 3 approaches for large b-cell lymphoma

Explore this study →

Sites in Calgary, Hamilton and 2 more cities

Official title: AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL

Large B-cell Lymphoma · AstraZeneca

Comparing 4 approaches for relapsed/refractory (r/r) mature b cell non Hodgkin

Explore this study →

Sites in Calgary, Montreal and 1 more city

Official title: A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL) · Arvinas Inc.

Testing Obinutuzumab with Glofitamab for b-cell non-hodgkins lymphoma

Explore this study →

Sites in Calgary and Winnipeg

Official title: A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

B-Cell Non-Hodgkins Lymphoma · Hoffmann-La Roche

Testing glofitamab for diffuse large b cell lymphoma (DLBCL)

Explore this study →

Sites in Toronto and Montreal

Official title: Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL)

Diffuse Large B Cell Lymphoma (DLBCL) · University Health Network, Toronto

Testing Pembrolizumab with Bendamustine Hydrochloride for classical Hodgkin lymphoma

Explore this study →

One site, in Toronto

Official title: Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma

Classical Hodgkin Lymphoma · University Health Network, Toronto

Comparing Gemcitabine with Brentuximab vedotin for Hodgkin lymphoma

Explore this study →

Sites in Montreal, Calgary and 9 more cities

Official title: Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma

Hodgkin Lymphoma · Canadian Cancer Trials Group

Comparing Soquelitinib with Belinostat for not otherwise specified peripheral t-cell lymphoma

Explore this study →

Sites in Ottawa, Toronto and 1 more city

Official title: Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

Peripheral T-Cell Lymphoma, Not Otherwise Specified · Corvus Pharmaceuticals, Inc.

Testing TBI-2001 with Cyclophosphamide for relapsed or refractory CD19+ b-cell lymphoma

Explore this study →

One site, in Toronto

Official title: Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL

Relapsed or Refractory CD19+ B-cell Lymphoma · University Health Network, Toronto

Testing Methotrexate with Rituximab (where available) for non-hodgkin lymphoma

Explore this study →

Sites in Calgary, Hamilton and 6 more cities

Official title: Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma

Non-hodgkin Lymphoma · Canadian Cancer Trials Group

Testing Zanubrutinib with Sonrotoclax for mantle cell lymphoma

Explore this study →

Sites in Edmonton, Toronto and 1 more city

Official title: Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy

Mantle Cell Lymphoma · Canadian Cancer Trials Group

Comparing 3 approaches for chronic lymphocytic leukaemia or small lymphocytic lymphoma

Explore this study →

Sites in Montreal, Calgary and 5 more cities

Official title: Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)

Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV · AstraZeneca

Comparing 8 approaches for lugano classification limited stage Hodgkin lymphoma AJCC v8

Explore this study →

Sites in Montreal, Calgary and 11 more cities

Official title: A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 · National Cancer Institute (NCI)

Comparing 3 approaches for non-hodgkin lymphoma

Explore this study →

Sites in Montreal, Toronto and 1 more city

Official title: A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

Lymphoma, Non-Hodgkin · Eli Lilly and Company

Comparing 3 approaches for large b-cell lymphoma

Explore this study →

One site, in Toronto

Official title: A Study to Evaluate Zanubrutinib and Tislelizumab in Progressive Lymphoma Post CAR-T

Large B-cell Lymphoma · University Health Network, Toronto

Comparing 3 approaches for untreated follicular lymphoma

Explore this study →

Sites in Barrie, Chicoutimi and 8 more cities

Official title: A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

Untreated Follicular Lymphoma · AstraZeneca

Comparing Obinutuzumab with Rituximab for lymphoma

Explore this study →

Sites in London, Ottawa and 1 more city

Official title: A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

Lymphoma · Hoffmann-La Roche

Comparing TLN-121 with zeprumetostat for lymphoma

Explore this study →

One site, in Vancouver

Official title: TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas

Lymphoma · Treeline Biosciences, Inc.

Comparing cemacabtagene ansegedleucel with Foresight CLARITY™ IUO MRD test, for large b-cell lymphoma

Explore this study →

Sites in Montreal, Calgary and 3 more cities

Official title: Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

Large B-cell Lymphoma · Allogene Therapeutics

Comparing 14 approaches for non-hodgkin lymphoma

Explore this study →

Sites in Edmonton, Kelowna and 8 more cities